Slide 1: Second Quarter 2009 Webcast
Exhibit 99.1 Second Quarter 2009 Webcast July 23, 2009
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation, made on July 23, 2009, includes forward-looking statements based on current expectations and Alcon does not undertake the obligation to update the forward-looking information or statements. These expectations could differ materially from actual results and ar
Slide 3: Business Overview
Business Overview Kevin Buehler President and Chief Executive Officer
Slide 4: Delivering Against Expectations, Investing in the Future
Delivering Against Expectations, Investing in the Future Organic sales growth of 3.3% in line with expectations (-3.4% reported)* – Higher TobraDex impact in Q2 – Strong Q208 comparable – Currency headwind less than anticipated Diligent management of SG&A contributes to 3.2% rise in diluted EPS – Re
Slide 5: Q2 2009 Geographic Sales and Growth
Q2 2009 Geographic Sales and Growth Q2 2009 Sales by Geography $281 Reported: - 8.2% Emerging Constant Currency*: + 8.1% Markets $790 16.8% Reported: 0.3% U.S. 47.1% Developed International 36.1% $606 Reported: - 5.6% Constant Currency*: + 4.8% (dollars in millions) * Constant currency sales growth
Slide 6: U.S. Pharmaceutical Category Growth Comparisons
U.S. Pharmaceutical Category Growth Comparisons U.S. Prescription Change for Key Categories vs. Prior Year Growth above Growth below 2008 growth 12.0% 2008 growth 10.9% 8.1% 8.0% 7.7% 2008 2009 4.1% 4.0% 3.0% 0.5% 0.8% 0.0% PG TCAI NSAID FQ Otic Ocular Allergy -4.0% -3.4% -3.0% -3.2% -4.2% -5.3% -8.
Slide 7: Gaining Market Share in Key Categories
Gaining Market Share in Key Categories Global** U.S. RX Growth MAY YTD MAY YTD Brand Market Brand Market TRAVATAN® Family 23.5 % 6.1 % 21.6% 3.0% Azopt® + Azarga® 11.3% 7.7% 9.7% 7.7% Vigamox® * 8.9% 1.4% -5.9% -5.3% NEVANAC® 71.7% 0.5% 8.7% 8.1% Patanol® + 29.3% 12.2% -3.2% -4.2% PatadayTM CIPRODEX
Slide 8: TRAVATAN Family Continues Glaucoma Market Success
TRAVATAN® Family Continues Glaucoma Market Success Alcon Global Prostaglandin Market Share TRAVATAN® Family has gained 6.2 share points following DuoTravTM and TRAVATAN Z® launches 22% 20.8% 20% 18% 16% 14.6% 14% 12% 10% 8% 6% 4% 2% 0% Q3 06 Q4 06 Q1 07 Q2 07 Q3 07 Q4 07 Q1 08 Q2 08 Q3 08 Q4 08 Q1 0
Slide 9: AZARGA Adds to Azopt Growth Opportunity
AZARGA® Adds to Azopt® Growth Opportunity Global TCAI and TCAI Combination Share TCAI and TCAI Combination Rx Distribution Azopt® Family has gained 9.6 share Azopt® makes up 69.9 percent points since Q1 2005 of the TCAI category 34% 33.2% 32% ® ® AZOPT AZARGA 30% 28% 26% 23.6% 24% 22% Azopt® 20% 18%
Slide 10: Impact of Generic Brimonidine 0.15% Launch
Impact of Generic Brimonidine 0.15% Launch U.S. Alpha-Agonists Category Share (As of May 2009) Alphagan P is an Alpha-Agonist used as an adjunctive therapy for glaucoma – U.S. sales of over $200M Alcon is the generic provider of brimonidine 0.15% in the United States 42.7% Will begin to see the reve
Slide 11: Global IOL Growth is Projected to Continue
Global IOL Growth is Projected to Continue IOL Unit Projections IOL Revenue Projections IOL Unit expected to grow at 3.8% IOL Revenue expected to grow at 8.2% 22.5 CAGR from 2009 to 2014 $3.5 CAGR from 2009 to 2014 $3.13 20.0 19.1 $3.0 17.5 15.9 $2.5 (units in millions) (dollars in billions) 15.0 $2
Slide 12: Bringing New Momentum to Premium IOL Categories
Bringing New Momentum to Premium IOL Categories U.S. Acrysof® ReSTOR® and Toric Implant Card Data 55,000 50,000 48,525 45,000 39,487 40,000 (implanted units) 35,000 30,000 25,000 20,000 15,000 10,000 5,000 0 Q2 2008 Q3 2008 Q4 2008 Q1 2009 Q2 2009 ® ReSTOR Toric Source: Company Data
Slide 13: Advanced Technology IOL Sales Accelerating
Advanced Technology IOL Sales Accelerating $70 $66.1 $60 $50 (dollars in millions) $40 $30 $20 $10 $- Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 05 05 05 05 06 06 06 06 07 07 07 07 08 08 08 08 09 09 ReSTOR® ReSTOR® CMS Toric Toric CMS ReSTOR® ReSTOR® +3.0 & Toric IQ Launch Decision Launch
Slide 14: Systane Ultra Leading Market Share Gains in Dry Eye
Systane® Ultra Leading Market Share Gains in Dry Eye U.S. Systane® Family Equivalent Unit Market Share Alcon has a 22.5 percent U.S. market share in the total Dry Eye category 18% 16% 16.8% 14% 15.5% 13.7% 12% 10% 8% 6% Systane® Ultra 4.2% 4% Launch 2% 0% 7 7 7 7 8 8 8 8 9 9 10 20 30 40 10 20 30 40
Slide 15: Commitment to Innovation
Commitment to Innovation Largest R&D organization in ophthalmology Broad array of programs at all stages of development to address unmet medical needs in critical areas – Glaucoma – Retinal disease – Dry eye – Cataract R&D strategic components – Access to external compounds – Internal development –
Slide 16: Key R&D Pipeline Activities
Key R&D Pipeline Activities Early-Stage Mid- to Late-Stage Global Registration Cilomilast (dry eye) TobraDex ST® Azarga® (EU) NVC-422 (anti-infective) Moxifloxacin, new formulation VIGAMOX® (EU) Tandospirone (AMD) MoxiDex Otic CILODEX® (EU) RTKi (AMD) Travatan® APS DuoTrav™ (Japan) VEGF (wet AMD, DM
Slide 17: Financial Review
Financial Review Rick Croarkin Senior Vice President, Finance and Chief Financial Officer
Slide 18: Sales
Sales Q2 YTD (dollars in millions) (dollars in millions) -3.4% Reported -3.1% Reported +3.3% Organic Growth* +4.1% Organic Growth* $1,800 $3,400 $1,675 $1,736 $1,677 $3,200 $3,272 $3,170 $1,550 $3,000 $1,425 $1,300 $2,800 Q2 2008 Q2 2009 Q2 2008 Q2 2009 * Constant currency sales growth and organic s
Slide 19: Gross Profit
Gross Profit Q2 YTD (dollars in millions) (dollars in millions) $1,500 $2,800 - 4.5% - 2.4% $1,375 $2,459 $2,300 $2,401 $1,321 $1,250 $1,262 $1,800 $1,125 $1,000 $1,300 Q2 2008 Q2 2009 Q2 YTD 2008 Q2 YTD 2009 % of 76.1% 75.3% 75.2% 75.7% Sales Highlights Difficult comparable: Q208 reported sales gre
Slide 20: Operating Income
Operating Income Q2 YTD (dollars in millions) (dollars in millions) $700 $1,200 - 2.2% 0.0% $650 $1,146 $1,146 $646 $1,100 $632 $600 $1,000 $550 $500 $900 Q2 2008 Q2 2009 Q2 YTD 2008 Q2 YTD 2009 % of Sales 37.2% 37.7% 35.0% 36.2% Highlights Reduction in SG&A a result of cost management programs and
Slide 21: Net Earnings
Net Earnings Q2 YTD (dollars in millions) (dollars in millions) $650 $1,200 + 2.6% + 3.8% $600 EPS $3.44* EPS $1.94* EPS $1.88* EPS $3.30* $1,000 $1,034 $582 $996 $550 $567 $500 $800 Q2 2008 Q2 2009 Q2 YTD 2008 Q2 YTD 2009 % of Sales 32.6% 34.7% 30.4% 32.6% Highlights Positive contribution from othe
Slide 22: 2009 Full Year Financial Guidance Revision
2009 Full Year Financial Guidance Revision • Organic growth in the mid-single digits • Diluted earnings per share: U.S. GAAP EPS guidance $6.20 - $6.35 Restructuring charge (0.05) (0.05) Adjusted EPS guidance $6.25 - $6.40 Note: Adjusted diluted EPS measures the results of the company's operations w
Slide 23: Second Quarter 2009 Webcast
Second Quarter 2009 Webcast July 23, 2009
Slide 24: Non-GAAP Reconciliations
Non-GAAP Reconciliations ALCON, INC. AND SUBSIDIARIES Global Sales (USD in millions) Three Months Ended Foreign June 30, Currency Organic 2009 2008 Change Change Change Geographic Sales Alcon United States: Pharmaceutical $ 391 $ 408 (4.2) % -- % (4.2) % Surgical 296 276 7.2 -- 7.2 Consumer Eye Care
Slide 25: Non-GAAP Reconciliations
Non-GAAP Reconciliations ALCON, INC. AND SUBSIDIARIES Global Sales (USD in millions) Three Months Ended Foreign June 30, Currency Organic 2009 2008 Change Change Change Global Product Sales Infection/inflammation $ 208 $ 231 (10.0) % (6.1) % (3.9) % Glaucoma 274 253 8.3 (8.3) 16.6 Allergy 160 168 (4
Slide 26: Non-GAAP Reconciliations
Non-GAAP Reconciliations ALCON, INC. AND SUBSIDIARIES Global Sales (USD in millions) Six Months Ended Foreign June 30, Currency Organic 2009 2008 Change Change Change Geographic Sales Alcon United States: Pharmaceutical $ 698 $ 726 (3.9) % -- % (3.9) % Surgical 554 530 4.5 -- 4.5 Consumer Eye Care 1
Slide 27: Non-GAAP Reconciliations
Non-GAAP Reconciliations ALCON, INC. AND SUBSIDIARIES Reconciliation of Non-GAAP Financial Measures Foreign Currency Organic Change Change Change Emerging market sales (8.3) % ( 16.4) % 8.1 % Global advanced technology intraocular lens sales 30.1 % ( 8.2) % 38.3 % Note: Organic change presents sales